What is Chardan Capital's Forecast for ABUS FY2025 Earnings?

Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - Analysts at Chardan Capital decreased their FY2025 earnings per share estimates for shares of Arbutus Biopharma in a research report issued on Tuesday, March 4th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will earn ($0.38) per share for the year, down from their prior forecast of ($0.30). Chardan Capital has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Arbutus Biopharma's current full-year earnings is ($0.39) per share. Chardan Capital also issued estimates for Arbutus Biopharma's FY2026 earnings at ($0.30) EPS.

A number of other brokerages have also commented on ABUS. HC Wainwright reissued a "buy" rating and set a $5.00 price objective on shares of Arbutus Biopharma in a report on Tuesday, January 21st. StockNews.com raised shares of Arbutus Biopharma from a "sell" rating to a "hold" rating in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $5.50.

Arbutus Biopharma Price Performance

Shares of ABUS stock traded down $0.05 during trading hours on Friday, hitting $3.06. 804,772 shares of the company's stock were exchanged, compared to its average volume of 1,020,573. Arbutus Biopharma has a 52 week low of $2.30 and a 52 week high of $4.73. The stock has a market cap of $579.85 million, a price-to-earnings ratio of -7.12 and a beta of 1.93. The stock's 50-day moving average is $3.34 and its 200-day moving average is $3.64.

Remove Ads

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Invesco Ltd. grew its position in shares of Arbutus Biopharma by 5.7% during the 4th quarter. Invesco Ltd. now owns 69,831 shares of the biopharmaceutical company's stock worth $228,000 after buying an additional 3,780 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Arbutus Biopharma by 10.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 40,179 shares of the biopharmaceutical company's stock worth $131,000 after acquiring an additional 3,870 shares during the period. Clear Harbor Asset Management LLC raised its position in shares of Arbutus Biopharma by 6.7% during the 4th quarter. Clear Harbor Asset Management LLC now owns 79,761 shares of the biopharmaceutical company's stock valued at $261,000 after acquiring an additional 5,000 shares during the last quarter. Creative Planning lifted its stake in shares of Arbutus Biopharma by 13.8% in the 3rd quarter. Creative Planning now owns 49,500 shares of the biopharmaceutical company's stock valued at $191,000 after purchasing an additional 5,989 shares during the period. Finally, Teacher Retirement System of Texas lifted its stake in shares of Arbutus Biopharma by 18.7% in the 4th quarter. Teacher Retirement System of Texas now owns 42,144 shares of the biopharmaceutical company's stock valued at $138,000 after purchasing an additional 6,644 shares during the period. 43.79% of the stock is currently owned by institutional investors and hedge funds.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.